Hastalara Baslanan Antiretrovital Tedavi Rejimleri Antiretroviral Tedavi Rejimleri Sayi (%) 2 NRTI + INI 97 (49.5) 2 NRT +
NNRTI 16 (8.2) 2 NRTI + PI 83 (42.3) NRTI: nukleozid revers transkriptaz inhibitoru, INI: integraz inhibitoru,
NNRTI: nonnukleozid revers transkriptaz inhibitoru, PI: proteaz inhibitoru.
In primary analyses, women in the switch arm had significant improvements in total and LDL cholesterol but did not have a statistically significant improvement in VAT compared to women continuing an
NNRTI or PI [40].
If the patient is on an NNRTI-based regimen, stop the
NNRTI first and the NRTIs after 5-7 days (however, if the patient is in liver failure, stop all ART immediately).
Both schemes refer to the combination of 2 NRTI +
NNRTI and require a lower daily intake of tablets, as shown in Table 1.
While 111 people (44%) were taking a protease inhibitor when they joined the study, 92 (36%) were taking a nonnucleoside reverse transcriptase inhibitor (
NNRTI).
The drug, part of a category of medicines known as non-nucleoside reverse transcriptase inhibitors (
NNRTIs), is said to work by blocking the virus' ability to replicate in the patient's blood.
Newer antiretrovirals, used for more treatment-experienced patients, are still in the registration process, such as the second-generation
NNRTI etravirine (ETV) and the integrase inhibitor raltegravir (RLT).
In terms of antiretroviral drug regimens, HIV-2 is intrinsically resistant to non nuclesoside reverse transcriptase inhibitors (
NNRTI) such as nevirapine and efavirenz and not all the protease inhibitors (PIs) provide good viral suppression (15).
Antiretroviral histories of the aging-up cluster often mirror those of adults who began treatment in the pre-HAART era with single or double nucleosides, then added a protease inhibitor (PI) or nonnucleoside (
NNRTI) to a faltering antiretroviral duo and ended up with multiple resistance mutations and multiclass failure.
Bone densities were retested after 48 weeks of combination HIV therapy with a nonnucleoside reverse transcriptase inhibitor (
NNRTI) and nucleoside reverse transcriptase inhibitors (NRTIs), or an
NNRTI and a boosted protease inhibitor, or two NRTIs and a boosted protease inhibitor.
In return, Glaxo secures exclusive worldwide rights to IDX899, a novel non-nucleoside reverse transcriptase inhibitor (
NNRTI) drug in mid-stage Phase II clinical tests for HIV/AIDS that is suitable for once-a-day administration.
This review focuses on the new protease inhibitors (PI) and non-nucleoside reverse transcriptase inhibitors (
NNRTI) that are currently available for clinicians to prescribe and explores their potential niche in antiretroviral treatment choices.